SCHEDULE: Shareholder Group Pushes for Board Seat at Alaunos Therapeutics

A group of shareholders, led by Adrian Price, has requested the appointment of Gerald W. Bruce to the Board of Directors of Alaunos Therapeutics, Inc. to enhance shareholder value.

Summary

• A group of 18 individuals, collectively referred to as the Reporting Persons, have filed an Amendment No. 2 to Schedule 13D concerning their holdings in Alaunos Therapeutics, Inc.
• The group beneficially owns an aggregate of 189,061 shares of Alaunos Therapeutics, Inc. common stock, representing 8.6% of the class.
• On December 4, 2025, Adrian Price, on behalf of the Reporting Persons, sent a letter to the Board of Directors of Alaunos Therapeutics, Inc., formally requesting the appointment of Gerald W. Bruce as a director.
• The stated purpose of this action is to help create shareholder value, and the Reporting Persons intend to continue these efforts.
• The Reporting Persons reserve the right to purchase or sell common stock of Alaunos Therapeutics, Inc. and to take other actions described in subsections (a) through (j) of Item 4 of Schedule 13D.

Sentiment

Score: 6

Explanation: The filing indicates activist shareholder engagement, which can be a catalyst for change and value creation, but also introduces potential for conflict and uncertainty. The explicit intent to create shareholder value is positive, but the need for such intervention suggests underlying issues that require addressing.

Positives

• Activist shareholder engagement often signals a push for improved corporate governance and strategic direction, potentially unlocking shareholder value.
• The Reporting Persons explicitly state their efforts are aimed at creating shareholder value, aligning with investor interests.

Negatives

• The request for a board seat suggests dissatisfaction with the current management or board composition, which could indicate underlying issues within the company.
• Potential for a prolonged activist campaign or disagreements between the shareholder group and the existing board could create uncertainty and divert management's focus.

Risks

• A potential for a proxy contest or ongoing disputes could lead to instability and negatively impact the company's operations and stock performance.
• Management's attention and resources could be diverted from core business activities to address the activist campaign.

Future Outlook

The Reporting Persons intend to continue their efforts to create shareholder value and reserve the right to purchase or sell common stock and take other actions described in Schedule 13D.

Management Comments

• This letter requested the Board to appoint Gerald W. Bruce as a director.
• This letter was sent as part of the Reporting Persons' efforts to help create shareholder value, and the Reporting Persons intend to continue these efforts.
• The Reporting Persons may purchase and sell common stock of Alaunos in their sole discretion and at such times as they deem convenient, subject to applicable law.

Industry Context

Shareholder activism is a recurring theme in the biotechnology and pharmaceutical sectors, where companies often face pressure to optimize R&D pipelines, accelerate clinical development, or explore strategic transactions to enhance value. The request for a board seat suggests a belief that new perspectives or governance changes are necessary to navigate industry-specific challenges or capitalize on market opportunities.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if the activist campaign successfully drives positive changes, but also introduces uncertainty if a prolonged dispute arises.
• Board of Directors: Will need to consider and respond to the activist group's request, potentially leading to internal discussions or changes in strategy.
• Management: May face increased scrutiny and pressure to perform or adapt to new strategic directions if a new director is appointed or the activist campaign escalates.

Next Steps

• The Board of Directors of Alaunos Therapeutics, Inc. will need to consider and respond to the request for Gerald W. Bruce's appointment.
• The Reporting Persons may continue to engage with the company's management and board to further their goal of creating shareholder value.
• The Reporting Persons may, at their discretion, purchase or sell additional common stock of Alaunos Therapeutics, Inc.

Key Dates

Recommendation

The filing indicates significant shareholder activism with a clear intent to influence corporate governance by requesting a board seat. While this could be a catalyst for value creation, it also introduces uncertainty and potential for conflict. Investors should hold to observe how the company's board responds and the subsequent actions of the activist group, as the outcome will dictate future performance.

Keywords

Alaunos Therapeutics, Shareholder Activism, Schedule 13D, Board Appointment, Corporate Governance, Gerald W. Bruce, Adrian Price, Biotechnology, Pharmaceuticals